Corbus (NASDAQ: CRBP) CMO offloads shares in tax-related RSU sale

Rhea-AI Filing Summary

Corbus Pharmaceuticals Holdings, Inc. Chief Medical Officer Dominic Smethurst reported an open-market sale of 6,097 shares of common stock at a weighted average price of $8.2994 per share. The sale was mandated to cover tax withholding on vesting RSUs and was not a discretionary trade. After this transaction, he directly holds 89,790 shares, including 73,765 unvested RSUs that remain subject to their vesting schedules.

Insider Trade Summary

Net Seller: 6,097 shares ($50,601)

Net Sell 1 txn

Insider Smethurst Dominic

Role Chief Medical Officer

Sold 6,097 shs ($51K)

Type	Security	Shares	Price	Value
Sale	Common Stock, par value $0.0001 per share	6,097	$8.2994	$51K

Holdings After Transaction: Common Stock, par value $0.0001 per share — 89,790 shares (Direct)

Footnotes (1)

1. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.20 to $8.35. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. This amount includes 73,765 unvested RSUs subject to each grant's vesting schedule as previously reported.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Smethurst Dominic

(Last) (First) (Middle)

C/O CORBUS PHARMACEUTICALS HOLDINGS, INC

500 RIVER RIDGE DRIVE

(Street)

NORWOOD MA 02062

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Corbus Pharmaceuticals Holdings, Inc. [ CRBP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.0001 per share	03/02/2026		S(1)		6,097	D	$8.2994(2)	89,790(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

2. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.20 to $8.35. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. This amount includes 73,765 unvested RSUs subject to each grant's vesting schedule as previously reported.

	/s/ Meghan Houghton, Attorney-in-Fact for Dominic Smethurst	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Corbus Pharmaceuticals (CRBP) report for Dominic Smethurst?

Corbus Pharmaceuticals reported that Chief Medical Officer Dominic Smethurst sold 6,097 shares of common stock. The weighted average sale price was $8.2994 per share, and the transaction was recorded as an open-market sale on March 2, 2026, tied to RSU tax withholding.

Why did CRBP’s Chief Medical Officer sell 6,097 shares of stock?

The 6,097 shares were sold solely to cover tax withholding obligations arising from the vesting and settlement of Restricted Stock Units. The company required a “sell to cover” transaction, so this sale did not represent a discretionary decision by the executive to reduce his investment.

At what price were the Corbus Pharmaceuticals shares sold in this Form 4?

The filing reports a weighted average sale price of $8.2994 per share. Footnotes explain the shares were sold in multiple trades, with individual prices ranging from $8.20 to $8.35, and detailed trade breakdowns are available upon request from the reporting person.

How many Corbus Pharmaceuticals (CRBP) shares does Dominic Smethurst hold after the sale?

After the tax-related sale, Dominic Smethurst directly holds 89,790 shares of Corbus Pharmaceuticals common stock. This total includes 73,765 unvested Restricted Stock Units that remain subject to their respective vesting schedules as previously disclosed in earlier compensation-related filings.

Are the 73,765 RSUs in the CRBP Form 4 already vested shares?

No, the 73,765 RSUs referenced in the filing are unvested awards. They are subject to each grant’s vesting schedule. These RSUs may convert into common shares in the future as vesting conditions are satisfied, consistent with the terms previously reported.

Was the CRBP insider sale by Dominic Smethurst a discretionary transaction?

The filing specifies the sale was not discretionary. Corbus Pharmaceuticals elected to satisfy tax withholding obligations from RSU vesting through a mandated “sell to cover” transaction, meaning the shares were automatically sold to pay taxes rather than voluntarily liquidated by the executive.